Table 9. Ongoing selected clinical trials targeting the FGFR pathway in solid tumor and hematologic malignancies continued.

Drug	Mechanism of action	Phase	Study population	Clinicaltrials.gov Identification
Regorafenib	Multikinase inhibitor including FGFR	2	Refractory epithelial ovarian carcinoma (serous, clear cell, endometrioid, mucinous, mixed, carcinosarcoma and others), fallopian tube and primary peritoneal carcinoma)	NCT02736305
Sunitinib	Multikinase inhibitor including FGFR	PS	Refractory solid tumors harboring RET fusion positive or FGFR2 amplification	NCT02450123
Sunitinib	Multikinase inhibitor including FGFR	PS	RET fusion positive or FGFR2 fusion/other FGFR mutation Refractory solid tumor and/or specific sensitivity to Sunitinib by Avatar scan	NCT02691793
TAS120	FGFR TKI	1	Advanced metastatic solid tumors with or without abnormalities of FGF/FGFR who have failed all standard therapies or for whom standard therapy does not exist or multiple myeloma with amplification, mutation or translocation or other associated abnormalities of FGF/FGFR who have failed all standard therapies or for whom standard therapy does not exist	NCT02052778
U3-1784	FGFR4 monoclonal antibody	1	Refractory solid tumors	NCT02690350
XL228	Multi-targeted kinase inhibitor IGF-1R, Src, FGFR, and BCR-Abl	1	Refractory solid tumors, lymphoma, or multiple myeloma	NCT00526838

Abbreviations: Fibroblast growth factor (FGF), fibroblast growth factor receptor (FGFR), not reported (NR), estrogen receptor positive (ER+), tyrosine kinase inhibitor (TKI), bacillus calmette-Guerin (BCG), small cell lung cancer (SCLC), Non-small cell lung cancer (NSCLC), squamous non-small cell lung cancer (sqNSCLC), pilot study (PS), glioblastoma multiforme (GBM), hepatocellular carcinoma (HCC), Malignant pleural mesothelioma (MPM), immunohistochemistry (IHC), urothelial carcinoma (UC).www.clinicaltrials.gov accessed on April 22^nd 2016.